We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cibus Inc (CBUS) USD0.0001 A

Sell:$9.08 Buy:$10.63 Change: $0.12 (1.20%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$9.08
Buy:$10.63
Change: $0.12 (1.20%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$9.08
Buy:$10.63
Change: $0.12 (1.20%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.

Contact details

Address:
6455 Nancy Ridge Drive
SAN DIEGO
92121
United States
Telephone:
+1 (858) 4500008
Website:
https://calyxt.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CBUS
ISIN:
US17166A1016
Market cap:
$245.39 million
Shares in issue:
25.46 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Rory Riggs
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Peter Beetham
    President, Co-Founder, Chief Operating Officer, Director
  • Greg Gocal
    Co-Founder, Executive Vice President, Chief Scientific Officer
  • Wade King
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.